Where does Adaptimmune Limited rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Adaptimmune Limited ranks #11,149 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Adaptimmune Limited hold?

Adaptimmune Limited holds 27 US utility patents granted between 2015 and 2024, spanning 9 technology areas.

What is Adaptimmune Limited's Innovation Score?

Adaptimmune Limited has an Innovation Score of 38.4 out of 100 (top 41% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Adaptimmune Limited focus on?

Adaptimmune Limited's top technology area is C07K (Peptides) with 23 patents, ranking #423 of 3,615 assignees active in that subclass. Grants appear in 9 CPC subclasses total.

Is Adaptimmune Limited's patent grant rate increasing or decreasing?

Adaptimmune Limited's recent grant velocity is +70% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Adaptimmune Limited's patents?

Adaptimmune Limited's patents average 13.3 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Adaptimmune Limited patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Adaptimmune Limited

USPTO PatentsView assignee record - 27 granted patents across 9 technology areas, recorded in grant years 2015–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (Peptides).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Adaptimmune ranks #11,149 of 49,997 tracked US assignees by granted-patent volume, with 27 patents across 9 technology areas.

#11,149
of 49,997 US assignees by volume: Top 41%
by Innovation Score (38.4/100): 13.3
avg claims per patent: +70%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R11149 · Foreign Corporation #11,149 · 27 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

GRANTS-SMALL 27 grants
UPPER-Q #11,149/49,997
PHOTO-FINISH Addepar
CPC-NARROW C07K · 9 areas
INNOV-THIN 38.4/100
CLAIMS-RICH 13.3 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-SURGE +70% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Addepar, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Adaptimmune’s 38.4 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 11.5 pts (30%) Velocity 8.3 pts (22%) Breadth 10.6 pts (28%) Claim depth 8.0 pts (21%)

Qualcomm Incorporated · highest

85
Adaptimmune · this assignee

38
BAE Systems Imaging… · near

38
Laurus Labs · near

38
Orion · near

38
Tokyo Women's… · near

38
3D Lighting… · lowest

7

What this shows Adaptimmune's Innovation Score is 38.4/100 (top 41% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Adaptimmune?

Each dot is one of Adaptimmune’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Adaptimmune’s own 13.3 claims/patent is at or below the 15.3 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Adaptimmune vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Adaptimmune's grants concentrate

Adaptimmune Limited is a focused PatentsView assignee: 9 CPC subclasses with 85.2% of grants classified under C07K (Peptides). Peak complete grant year is 2021 (6 grants) versus a trough of 1 in 2017. By volume, Adaptimmune sits between Apollo Education Group, Inc. and Akili Interactive Labs, Inc..

Adaptimmune's three-year grant acceleration

Adaptimmune Limited shows 10 grants in 2022–2024 against only 8 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Apollo Education…

27
Arcadia Bioscienc…

27
Asahi Group Holdi…

27
Assa Abloy Reside…

27
Addepar

27
Advanced Flexible…

27
Affirm

27
Akili Interactive…

27
Adaptimmune ◀

27

What this shows Adaptimmune holds 27 patents at rank #11,158, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Adaptimmune

By rank, the assignees closest to #11,158 in granted patent volume.

Leaders in C07K (Peptides)

Other assignees with the most granted patents in Adaptimmune's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Adaptimmune, neither rank-band nor same-CPC leaders (those blocks stay above). In C07K (Peptides), Adaptimmune ranks #423 of 3,615 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (38 here).

Tokyo Women's Medical University 38 BAE Systems Imaging Solutions Inc. 38 Laurus Labs Limited 38 Orion Corporation 38

Adaptimmune's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

38 Top 41% higher than 59% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Adaptimmune Limited patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	2	7.4%
2016	4	14.8%
2017	1	3.7%
2018	2	7.4%
2019	1	3.7%
2020	1	3.7%
2021	6	22.2%
2022	1	3.7%
2023	4	14.8%
2024	5	18.5%

Which technologies does Adaptimmune Limited patent most?

C07K - Peptides 23

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 22

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 21

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 20

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 6

C40B - Combinatorial CHEMISTRY; Libraries, e.g. Chemical Libraries 4

G16B - Bioinformatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR Genetic OR Protein-related Data Processing IN Computational Molecular Biology 2

G16C - Computational CHEMISTRY; CHEMOINFORMATICS; Computational Materials Science 2

C12Y - Enzymes 2

Top 9 of 9 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Adaptimmune Limited's patent record in context - here's where to go next.

Adaptimmune Limited's lead technology class is C07K (Peptides), 85.2% of its portfolio - see every assignee active in that class. Explore C07K
Ranked #11,149 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Adaptimmune Limited against Apollo Education Group, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 38.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.